Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656630 · ClinicalTrials.gov registry record · Phase 2
Medication Development in Alcoholism: Acamprosate Versus Naltrexone
A Phase 2 study, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00656630 is a Phase 2 study that has completed, run by The Scripps Research Institute. The registered enrollment target is 68 participants.
The verdict
NCT00656630, a Phase 2 study, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.
Interventions
- DRUG Placebo
- DRUG Acamprosate
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656630
The ClinicalTrials.gov registry entry for NCT00656630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Scripps Research Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00656630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656630 about?
NCT00656630 is a clinical study titled "Medication Development in Alcoholism: Acamprosate Versus Naltrexone". The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.
What is the current status of trial NCT00656630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2007-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00656630?
The interventions under investigation include: Placebo (DRUG), Acamprosate (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00656630?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.